PCSK9 LDL Cholesterol Regulation

Created for Biopharmaceutical Client
The project

This medical animation explores the role of low density lipoprotein cholesterol (LDL-C) in atherosclerotic cardiovascular disease via regulation of LDL-C levels in the liver. By contrasting the LDL-C processing with and without PCSK9, we demonstrate how the latter is a therapeutic target for lowering LDL-C levels in hyperlipidemia. The medical animation goes on to explain the mechanism of action (MOA) of evolucumab, a PCSK9 inhibitor.

Created for
Biopharmaceutical client

COVID-19 Update:
In alignment with public health directives, we continue to prioritize the safety of our staff and uninterrupted service to our clients.
We are open for business. Wishing you good health and resilience. We’re all in this together.